glivec
novartis new zealand ltd - imatinib mesilate 119.5mg equivalent to 100 mg imatinib base - capsule - 100 mg - active: imatinib mesilate 119.5mg equivalent to 100 mg imatinib base excipient: colloidal silicon dioxide crospovidone gelatin iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - · treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). · treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. · treatment of adult patients with new diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+all) integrated with chemotherapy. · treatment of adult patients with relapsed or refractory ph+all as monotherapy. · treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. · treatment of adult patients with systemic mastocytosis (sm) without the d816v c-kit mutation or with c-kit mutational status unknown. · treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). · treatment of adult patients with kit+ (cd117) unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). · adjuvant treatment of adult patients following resection of kit+gist. · treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).
glivec
novartis new zealand ltd - imatinib mesilate 59.75mg equivalent to 50 mg imatinib base - capsule - 50 mg - active: imatinib mesilate 59.75mg equivalent to 50 mg imatinib base excipient: colloidal silicon dioxide crospovidone gelatin iron oxide yellow magnesium stearate microcrystalline cellulose titanium dioxide - · treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). · treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. · treatment of adult patients with new diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+all) integrated with chemotherapy. · treatment of adult patients with relapsed or refractory ph+all as monotherapy. · treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. · treatment of adult patients with systemic mastocytosis (sm) without the d816v c-kit mutation or with c-kit mutational status unknown. · treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). · treatment of adult patients with kit+ (cd117) unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). · adjuvant treatment of adult patients following resection of kit+gist. · treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).
glivec
novartis new zealand ltd - imatinib mesilate 119.5mg equivalent to imatinib base 100 mg; - film coated tablet - 100 mg - active: imatinib mesilate 119.5mg equivalent to imatinib base 100 mg excipient: colloidal silicon dioxide crospovidone hypromellose magnesium stearate microcrystalline cellulose opadry red 00f15613 opadry yellow 00f12951 purified water - · treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). · treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. · treatment of adult patients with new diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+all) integrated with chemotherapy. · treatment of adult patients with relapsed or refractory ph+all as monotherapy. · treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. · treatment of adult patients with systemic mastocytosis (sm) without the d816v c-kit mutation or with c-kit mutational status unknown. · treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). · treatment of adult patients with kit+ (cd117) unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). · adjuvant treatment of adult patients following resection of kit+gist. · treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).
glivec
novartis new zealand ltd - imatinib mesilate 478mg equivalent to imatinib base 400 mg; - film coated tablet - 400 mg - active: imatinib mesilate 478mg equivalent to imatinib base 400 mg excipient: colloidal silicon dioxide crospovidone hypromellose magnesium stearate microcrystalline cellulose opadry red 00f15613 opadry yellow 00f12951 purified water - · treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). · treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. · treatment of adult patients with new diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+all) integrated with chemotherapy. · treatment of adult patients with relapsed or refractory ph+all as monotherapy. · treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. · treatment of adult patients with systemic mastocytosis (sm) without the d816v c-kit mutation or with c-kit mutational status unknown. · treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). · treatment of adult patients with kit+ (cd117) unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). · adjuvant treatment of adult patients following resection of kit+gist. · treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).
new zealand diagnostics instant pregnancy test cassette
new zealand diagnostics ltd - bovine serum albumin 1ug; goat anti-mouse polyclonal antibody 8ug; murine monoclonal antibody to alpha hcg 1.5ug; murine monoclonal antibody to beta hcg 3ug - pregnancy test kit - active: bovine serum albumin 1ug goat anti-mouse polyclonal antibody 8ug murine monoclonal antibody to alpha hcg 1.5ug murine monoclonal antibody to beta hcg 3ug
new zealand diagnostics instant pregnancy test strip
new zealand diagnostics ltd - bovine serum albumin 1ug; goat anti-mouse polyclonal antibody 8ug; murine anti-beta-hcg monoclonal antibody-colloidal gold conjugate 3ug; murine monoclonal antibody to alpha hcg 1.5ug - pregnancy test kit - active: bovine serum albumin 1ug goat anti-mouse polyclonal antibody 8ug murine anti-beta-hcg monoclonal antibody-colloidal gold conjugate 3ug murine monoclonal antibody to alpha hcg 1.5ug
new myrex laboratories, inc. clin-gen clindamycin (as hydrochloride)
new myrex laboratories, inc. - drug - clindamycin (as hydrochloride) - clin-gen
new myrex laboratories, inc./ tgp pharma inc. kylezine clindamycin (as hydrochloride)
new myrex laboratories, inc. - drug - clindamycin (as hydrochloride) - kylezine
new myrex laboratories,inc. clin-gen clindamycin (as hydrochloride)
new myrex laboratories, inc. - drug - clindamycin (as hydrochloride) - clin-gen
venofundin 6%
b braun new zealand ltd - hetastarch 60 g; ; sodium chloride 9 g; ; - solution for infusion - 6 % - active: hetastarch 60 g sodium chloride 9 g excipient: water for injection